UTHealth Receives FDA Approval To Market New Coronary Flow Reserve Quantification Software
CHICAGO, Aug. 20, 2012 /PRNewswire/ -- Positron Corporation (OTCBB: POSC) a leading molecular imaging healthcare company, is pleased to announce the FDA's marketing approval of The University of Texas Health Science Center at Houston (UTHealth) Coronary Flow Reserve (CFR) quantification software, cfrQuant™.
The cfrQuant™ software was developed under the guidance of K. Lance Gould, M.D., and the Weatherhead PET Imaging Center of the UTHealth Medical School, with contributions of software segments from Positron Corporation.
Positron will distribute and support cfrQuant™ to its current and future U.S. based cardiac PET customers, under a licensing agreement with UTHealth. The cfrQuant™ software has been approved for use with 82Rb-chloride and 13N-ammonia. Dr. Gould has recused himself of receiving royalties in support of academic programs.
Joseph Oliverio, Chief Technology Officer of Positron stated, "The introduction of CFR, as a routine non-invasive measurement used in conjunction with cardiac PET imaging, provides a clear differentiator when compared to competing technologies; justifying the expansion of patient indication selection and approval for reimbursement. We believe cfrQuant™ will revolutionize the methodology of diagnosis and subsequent treatment of coronary disease, resulting in improved patient outcomes and cost savings within our heath care system. We look forward to the quick dissemination of this software due to the benefits and advantages it will provide."
K. Lance Gould, M.D. stated, "The capacity of non-invasive PET for quantitative myocardial perfusion using cfrQuant™ parallels the use of invasive, pressure-based Fractional Flow Reserve (FFR) for assessing physiologic stenosis severity as a guide to management and revascularization procedures. Sophisticated cardiac PET uniquely quantifies diffuse Coronary Artery Disease (CAD) and/or the combination of diffuse and